Find A Clinical Trial

Disease Type: Gynecologic

Trial ID 21369

PICCOLO: A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression

Principal Investigator
Robert L. Marsh, MD
3 Locations
Trial ID 21308
Sponsor ID Zentalis Pharmaceuticals

A Phase 1/2 Dose-Escalation and Dose-Expansion Study of ZN‑c3 in Combination with Niraparib in Subjects with Platinum-Resistant Ovarian Cancer

1 Location
Trial ID 21253
Sponsor ID FLORA-5

A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma(FLORA-5)

Principal Investigator
Robert L. Marsh, MD
3 Locations
Trial ID STRO-002-GM2
Sponsor ID Sutro Biopharma

A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor alpha Antibody Drug Conjugate (ADC), in Combination with Bevacizumab in Patients with Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers).

1 Location
Trial ID USOR 21400
Sponsor ID TJ004309STM103

A Phase 2 Clinical Study of TJ004309 in Combination with Atezolizumab in Patients with Advanced or Mets Ovarian Cancer and Selected Advanced Solid Tumors.

Trial ID 20298
Sponsor ID

Phase 2 Study of VS-6766 (Dual RAK/MEK Inhibitor) Alone and in Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

Principal Investigator
Mitul Gandhi, MD
5 Locations